雷奈酸锶
德诺苏马布
医学
骨质疏松症
特立帕肽
骨矿物
健骨
骨吸收
骨密度保护剂
牙科
内科学
出处
期刊:PubMed
日期:2006-08-31
卷期号:8 (4): 367-71
被引量:1
摘要
Currently a wide range of drugs efficient in osteoporotic fractures are on disposal. Bisfosphonates are the most important group, which are currently administered in a weekly dosage: Alendronate dose 70mg and Risedronate - 35mg. Since few months a therapy once a month with Ibandronate 150mg is also available. Apart from antyresorptive therapy there are also other groups of medications. Strontium Ranelate not only decreases bone resorption but also increases bone formation. Parathyroid hormone subcutaneous strongly promotes bone formation. Denosumab given subcutaneous once in half a year elevates bone mineral density. Hormone Replacement Therapy is not applied in prevention of osteoporotic fracture, however, it is still in use in treatment of disorders of menopause. In countries with correct health policy the doctors have complete possibility to adjust appropriate medications according to the patient's health state.
科研通智能强力驱动
Strongly Powered by AbleSci AI